首页 > 市场调查报告书 > 製药

亚太地区阿片类药物市场预测至 2030 年 - 区域分析 - 按产品、应用、给药途径和配销通路

市场调查报告书

商品编码

1637658

亚太地区阿片类药物市场预测至 2030 年 - 区域分析 - 按产品、应用、给药途径和配销通路

Asia Pacific Opioids Market Forecast to 2030 - Regional Analysis - by Product, Application, Route of Administration, and Distribution Channel

出版日期: 2024年11月22日 | 出版商:

The Insight Partners | 英文 93 Pages | 订单完成后即时交付

价格

简介目录图表

2022年亚太地区阿片类药物市值为24.0624亿美元，预计2030年将达到30.9177亿美元；预计2022年至2030年复合年增长率为3.2%。

慢性疼痛发生率激增推动亚太阿片类药物市场

心血管疾病、癌症、肌肉骨骼疾病和神经血管疾病等慢性疾病会降低免疫力，严重影响人的健康。此外，许多患有这些病症的患者会经历慢性疼痛。上述疾病在成人和老年族群中最常见。然而，儿童中这些疾病的病例也明显增加。慢性疼痛在运动员、运动员和曾经受伤的人中也很常见。根据NCBI（即国家生物技术资讯中心）发表的一项研究，全世界有20%的成年人患有疼痛，并且每年有10%新诊断出患有慢性疼痛。虽然疼痛影响所有人群，无论性别、种族/民族、收入、年龄或地理位置如何，但疼痛在世界各地的分布并不均匀。处方阿片类药物，包括氢可酮、羟考酮和吗啡，是有效的止痛药物，用于治疗因受伤、手术以及癌症和关节炎等健康状况引起的疼痛。

阿片类药物处方实践的增加可归因于保险报销计划，该计划激励阿片类药物而不是替代性疼痛治疗、鼓励更有效护理的成本结构以及将患者满意度与有效疼痛管理相结合的评估。因此，由于阿片类药物在疼痛管理方面的优势，对慢性病患者的需求不断上升。

亚太地区阿片类药物市场概况

据估计，中国患有末期疾病的老年人口不断增加，对鸦片类药物的需求将大幅增加。根据世界卫生组织（WHO）的数据，该国是老龄化人口成长最快的国家之一。根据同一来源，2019 年 60 岁及以上人口为 2.54 亿，65 岁及以上人口为 1.76 亿。此外，由于预期寿命的延长和出生率的下降，预计到 2040 年，中国约 28% 的人口（4.02 亿人）将年龄在 60 岁及以上。老年族群更有可能患有与疼痛相关的慢性健康问题，例如关节炎、背痛、癌症等。重大影响中国太平洋阿片类药物市场。在中国，新发患有严重病理性疼痛的癌症患者数量显着增加。根据 2020 年发表的一项研究《医生继续医学教育对中国癌痛治疗品质的影响》，中国政府鼓励使用阿片类镇痛药治疗中度至重度癌痛，这是广泛应用于全国三级医院、二级医院。由于鸦片类药物是三步骤镇痛阶梯的主要组成部分，建议用于缓解中度和重度癌症疼痛，因此提高对此类医疗状况和相关治疗的认识可以改善癌症疼痛的治疗计划。

亚太地区阿片类药物市场收入及 2030 年预测（百万美元）

亚太地区阿片类药物市场细分

亚太地区阿片类药物市场按产品、应用、给药途径、配销通路和国家分类。

根据产品，亚太地区鸦片类药物市场分为速释短效鸦片类药物和缓释长效型鸦片类药物。 2022年，速释短效鸦片类药物细分市场占据了更大的市场份额。芬等。缓释长效型鸦片类药物进一步细分为羟考酮、芬太尼、吗啡、美沙酮等。

从应用来看，亚太地区鸦片类药物市场分为疼痛管理、麻醉、止泻、止咳、戒瘾等。 2022 年，疼痛管理领域占据最大的市场。

依给药途径，亚太地区阿片类药物市场分为口服、注射及透皮贴片。 2022 年，口腔细分市场占据最大的市场份额。

按配销通路划分，亚太地区阿片类药物市场分为医院药房和零售药房。 2022年，医院药局部门将占据更大的市场份额。

按国家/地区划分，亚太地区阿片类药物市场分为中国、日本、印度、韩国、澳洲和亚太其他地区。 2022年，中国在亚太阿片类药物市场份额中占据主导地位。

Endo International plc、Mallinckrodt Plc、Neuraxpharm Pharmaceuticals SL、Mayne Pharma Group Ltd、Rusan Pharma Ltd 和 Teva Pharmaceutical Industries Ltd 是亚太阿片类药物市场上的一些领先公司。

Chronic diseases such as cardiovascular disease, cancer, musculoskeletal diseases, and neurovascular diseases critically affect a person's health by lowering immunity. Moreover, many patients suffering from these conditions experiences chronic pain. The diseases mentioned above are most common in adults and the geriatric population. Nevertheless, cases of these diseases are noticeably growing among children as well. Chronic pain is also common among sportspersons, athletes, and individuals living with past injuries. According to a study published in the NCBI (i.e., National Center for Biotechnology Information), 20% of adults suffer from pain worldwide, and 10% are newly diagnosed with chronic pain per year. While pain affects all populations, regardless of sex, race/ethnicity, income, age, or geography, it is not distributed equally across the world. Prescription opioids, including hydrocodone, oxycodone, and morphine, are potent pain-reducing medications that are used to treat pain caused by injuries, surgeries, and health conditions such as cancer and arthritis.

Increased opioid prescribing practices can be attributed to the insurance reimbursement programs that incentivize opioids over alternative pain treatments, cost structures that encourage more efficient care, and evaluations that combine patient satisfaction with effective pain management. Therefore, owing to the advantage of opioids in pain management, the demand is rising among patients with chronic diseases.

Asia Pacific Opioids Market Overview

The growing geriatric population in China suffering from terminal illnesses is estimated to significantly increase the demand for opioids. As per the World Health Organization (WHO), the country has one of the fastest-growing aging populations. Per the same source, 254 million people were aged 60 and above in 2019 and 176 million people were aged 65 and above. Also, ~28% of the population (402 million people) in China is expected to be aged 60 and above by 2040 due to increasing life expectancy and decreasing birth rates. Geriatric populations are more likely to experience chronic health conditions that are associated with pain, such as arthritis, back pain, cancer, etc. In such cases, opioids are used to manage chronic pain in older adults, which significantly influence the growth of the Asia Pacific opioids market in China. In China, the number of new cancer patients suffering from severe pathological pain has significantly increased. As per a study, "Impact of Continuing Medical Education for Physicians on the Quality of Cancer Pain Treatment in China," published in 2020, the government of China encourages the use of opioid analgesics for the treatment of moderate to severe cancer pain, which is widely available in tertiary hospitals and secondary hospitals across the country. As opioids are a major part of a three-step analgesic ladder and are recommended for relieving moderate and severe cancer pain, increasing awareness regarding such medical conditions and associated treatment can improve the treatment plan for cancer pain.

Asia Pacific Opioids Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Opioids Market Segmentation

The Asia Pacific opioids market is categorized into product, application, route of administration, distribution channel, and country.

Based on product, the Asia Pacific opioids market is segmented immediate release short acting opioid and extended release long acting opioid. The immediate release short acting opioid segment held a larger market share in 2022. The immediate release short acting opioid is further sub segmented into oxycodone, hydrocodone, tramadol, codeine, propoxyphene, and others. The extended release long acting opioid is further sub segmented into oxycodone, fentanyl, morphine, methadone, and others.

In terms of application, the Asia Pacific opioids market is categorized into pain management, anesthesia, diarrhea suppression, cough suppression, de-addiction, and others. The pain management segment held the largest market share in 2022.

By route of administration, the Asia Pacific opioids market is segmented into oral, injectable, and transdermal patch. The oral segment held the largest market share in 2022.

By distribution channel, the Asia Pacific opioids market is bifurcated into hospital pharmacies and retail pharmacies. The hospital pharmacies segment held a larger market share in 2022.

By country, the Asia Pacific opioids market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific opioids market share in 2022.

Endo International plc, Mallinckrodt Plc, Neuraxpharm Pharmaceuticals SL, Mayne Pharma Group Ltd, Rusan Pharma Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Asia Pacific opioids market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Opioids Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Surging Chronic Pain Incidence
- 4.1.2 Increasing Geriatric Population
4.2 Market Restraints
- 4.2.1 Increasing Drug Abuse
4.3 Market Opportunities
- 4.3.1 Strategic Initiatives by Market Players
4.4 Impact of Drivers and Restraints:

5. Opioids Market - Asia Pacific Analysis

5.1 Asia Pacific Opioids Market Overview
5.2 Asia Pacific Opioids Market Revenue (US$ Million), 2020-2030
5.3 Asia Pacific Opioids Market Forecast Analysis

6. Asia Pacific Opioids Market Analysis - by Product

6.1 Immediate Release Short Acting Opioid
- 6.1.1 Overview
- 6.1.2 Immediate Release Short Acting Opioid: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.1.2.1 Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
6.2 Extended Release Long-Acting Opioid
- 6.2.1 Overview
- 6.2.2 Extended Release Long-Acting Opioid: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.2.2.1 Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid

7. Asia Pacific Opioids Market Analysis - by Application

7.1 Pain Management
- 7.1.1 Overview
- 7.1.2 Pain Management: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Anesthesia
- 7.2.1 Overview
- 7.2.2 Anesthesia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Diarrhea Suppression
- 7.3.1 Overview
- 7.3.2 Diarrhea Suppression: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Cough Suppression
- 7.4.1 Overview
- 7.4.2 Cough Suppression: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.5 De-Addiction
- 7.5.1 Overview
- 7.5.2 De-Addiction: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Opioids Market Analysis - by Route of Administration

8.1 Oral
- 8.1.1 Overview
- 8.1.2 Oral: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8.2 Injectable
- 8.2.1 Overview
- 8.2.2 Injectable: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Transdermal Patch
- 8.3.1 Overview
- 8.3.2 Transdermal Patch: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Opioids Market Analysis - by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Opioids Market - Country Analysis

10.1 Asia Pacific
- 10.1.1 Asia Pacific: Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)
  - 10.1.1.1 Asia Pacific: Opioids Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.2 China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.2.1 China: Asia Pacific Opioids Market Breakdown, by Product
    - 10.1.1.2.2 China: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 10.1.1.2.3 China: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 10.1.1.2.4 China: Asia Pacific Opioids Market Breakdown, by Application
    - 10.1.1.2.5 China: Asia Pacific Opioids Market Breakdown, by Route of Administration
    - 10.1.1.2.6 China: Asia Pacific Opioids Market Breakdown, by Distribution Channel
  - 10.1.1.3 Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.3.1 Japan: Asia Pacific Opioids Market Breakdown, by Product
    - 10.1.1.3.2 Japan: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 10.1.1.3.3 Japan: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 10.1.1.3.4 Japan: Asia Pacific Opioids Market Breakdown, by Application
    - 10.1.1.3.5 Japan: Asia Pacific Opioids Market Breakdown, by Route of Administration
    - 10.1.1.3.6 Japan: Asia Pacific Opioids Market Breakdown, by Distribution Channel
  - 10.1.1.4 India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.4.1 India: Asia Pacific Opioids Market Breakdown, by Product
    - 10.1.1.4.2 India: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 10.1.1.4.3 India: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 10.1.1.4.4 India: Asia Pacific Opioids Market Breakdown, by Application
    - 10.1.1.4.5 India: Asia Pacific Opioids Market Breakdown, by Route of Administration
    - 10.1.1.4.6 India: Asia Pacific Opioids Market Breakdown, by Distribution Channel
  - 10.1.1.5 South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.5.1 South Korea: Asia Pacific Opioids Market Breakdown, by Product
    - 10.1.1.5.2 South Korea: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 10.1.1.5.3 South Korea: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 10.1.1.5.4 South Korea: Asia Pacific Opioids Market Breakdown, by Application
    - 10.1.1.5.5 South Korea: Asia Pacific Opioids Market Breakdown, by Route of Administration
    - 10.1.1.5.6 South Korea: Asia Pacific Opioids Market Breakdown, by Distribution Channel
  - 10.1.1.6 Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.6.1 Australia: Asia Pacific Opioids Market Breakdown, by Product
    - 10.1.1.6.2 Australia: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 10.1.1.6.3 Australia: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 10.1.1.6.4 Australia: Asia Pacific Opioids Market Breakdown, by Application
    - 10.1.1.6.5 Australia: Asia Pacific Opioids Market Breakdown, by Route of Administration
    - 10.1.1.6.6 Australia: Asia Pacific Opioids Market Breakdown, by Distribution Channel
  - 10.1.1.7 Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.7.1 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Product
    - 10.1.1.7.2 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 10.1.1.7.3 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 10.1.1.7.4 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Application
    - 10.1.1.7.5 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Route of Administration
    - 10.1.1.7.6 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Distribution Channel

11. Industry Landscape

11.1 Overview
11.2 Growth Strategies in Opioids Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Endo International plc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Mallinckrodt Plc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Neuraxpharm Pharmaceuticals SL
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Mayne Pharma Group Ltd
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Rusan Pharma Ltd
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Teva Pharmaceutical Industries Ltd
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. Asia Pacific Opioids Market Segmentation
Table 2. Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 4. Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 5. Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 6. Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 7. Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 8. Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 9. Asia Pacific: Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Country
Table 10. China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 11. China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 12. China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 13. China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 14. China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 15. China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 16. Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 17. Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 18. Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 19. Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 20. Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 21. Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 22. India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 23. India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 24. India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 25. India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 26. India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 27. India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 28. South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 29. South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 30. South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 31. South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 32. South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 33. South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 34. Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 35. Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 36. Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 37. Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 38. Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 39. Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 40. Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 41. Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 42. Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 43. Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 44. Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 45. Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 46. Recent Organic Growth Strategies in Opioids Market
Table 47. Recent Inorganic Growth Strategies in the Opioids Market
Table 48. Glossary of Terms, Opioids Market

List Of Figures

Figure 1. Asia Pacific Opioids Market Segmentation, by Country
Figure 2. Asia Pacific Opioids Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Opioids Market Revenue (US$ Million), 2020-2030
Figure 5. Asia Pacific Opioids Market Share (%) - by Product (2022 and 2030)
Figure 6. Immediate Release Short Acting Opioid: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Extended Release Long-Acting Opioid: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Asia Pacific Opioids Market Share (%) - by Application (2022 and 2030)
Figure 9. Pain Management: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Anesthesia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Diarrhea Suppression: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Cough Suppression: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. De-Addiction: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Asia Pacific Opioids Market Share (%) - by Route of Administration (2022 and 2030)
Figure 16. Oral: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Injectable: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Transdermal Patch: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Asia Pacific Opioids Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 20. Hospital Pharmacies: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Retail Pharmacies: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 22. Asia Pacific: Opioids Market, by Key Countries - Revenue (2022) (US$ Million)
Figure 23. Asia Pacific: Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 24. China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 26. India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 27. South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 30. Growth Strategies in Opioids Market